WIXOM, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the quarter and six months ended June 30, 2017.
Q2 2017 Financial Highlights
- Sales were $13.2 million compared to $13.4 in Q2 2016.
- Gross profit was $1.5 million, unchanged compared to Q2 2016.
- SG&A expense was $6.5 million compared $5.0 million in Q2 2016.
- R&D expense was $1.7 million compared to $2.1 million in Q2 2016.
- Net loss was $7.1 million or ($0.14) per share compared to a $5.4 million loss or ($0.11) per share in Q2 2016.
- Cash and investments were $43.2 million as of June 30, 2017.
- Net working capital was $56.1 million as of June 30, 2017.
Q2 YTD 2017 Financial Highlights
- Sales were $27.8 million, an increase of $0.8 million or 2.8% over the first six months of 2016.
- Gross profit was $3.9 million, an increase of $0.7 million or 21.1% over the first six months of 2016.
- SG&A expense was $12.6 million compared to $10.0 million in the first six months of 2016.
- R&D expense was $2.9 million compared to $3.4 million in the first six months of 2016.
- Net Loss was $11.8 million or ($0.23) per share compared to $10.2 million or ($0.20) per share in the first six months of 2016.
“Our immediate priority is to secure add-on reimbursement for Triferic and we continue to make solid progress in our efforts,” stated Mr. Robert L. Chioini, chairman and chief executive officer of Rockwell. “We are working with key leadership within the new administration including Health and Human Services and Centers for Medicare and Medicaid Services, and we continue to receive outstanding congressional support. Feedback reported from our Triferic drug sample program continues to be very favorable and there is clearly recognition in the medical community of the value that Triferic can bring to patient outcomes. Calcitriol manufacture is progressing well and we remain on track with our FDA submission.”
Conference Call Information
Rockwell Medical will be hosting a conference call to review its 2017 second quarter and year to date results on Wednesday, August 9, 2017 at 4:30 p.m. EDT. Investors are encouraged to call a few minutes in advance at (888) 487-0354, or for international callers (719) 325-2301, passcode #3956742 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/
About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information.
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Michael Rice, Investor Relations; 646-597-6979
Triferic® is a registered trademark of Rockwell Medical, Inc.
| ROCKWELL MEDICAL, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONSOLIDATED INCOME STATEMENTS | ||||||||||||||||
| For the three and six months ended June 30, 2017 and June 30, 2016 | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, 2017 | Three Months Ended June 30, 2016 | Six Months Ended June 30, 2017 | Six Months Ended June 30, 2016 | |||||||||||||
| Sales | $ | 13,243,107 | $ | 13,452,517 | $ | 27,835,361 | $ | 27,079,565 | ||||||||
| Cost of Sales | 11,744,819 | 11,962,989 | 23,979,601 | 23,895,111 | ||||||||||||
| Gross Profit | 1,498,288 | 1,489,528 | 3,855,760 | 3,184,454 | ||||||||||||
| Selling, General and Administrative | 6,541,179 | 5,014,370 | 12,641,894 | 10,001,111 | ||||||||||||
| Research and Product Development | 1,675,494 | 2,063,324 | 2,890,345 | 3,377,754 | ||||||||||||
| Operating Income (Loss) | (6,718,385 | ) | (5,588,166 | ) | (11,676,479 | ) | (10,194,411 | ) | ||||||||
| Interest and Investment Income | (364,599 | ) | 227,020 | (148,528 | ) | 413,582 | ||||||||||
| Income (Loss) Before Income Taxes | (7,082,984 | ) | (5,361,146 | ) | (11,825,007 | ) | (9,780,829 | ) | ||||||||
| Income Tax Expense | — | — | — | (404,527 | ) | |||||||||||
| Net Income (Loss) | $ | (7,082,984 | ) | $ | (5,361,146 | ) | $ | (11,825,007 | ) | $ | (10,185,356 | ) | ||||
| Basic Earnings (Loss) per Share | $ | (0.14 | ) | $ | (0.11 | ) | $ | (0.23 | ) | $ | (0.20 | ) | ||||
| Diluted Earnings (Loss) per Share | $ | (0.14 | ) | $ | (0.11 | ) | $ | (0.23 | ) | $ | (0.20 | ) | ||||
| ROCKWELL MEDICAL, INC. AND SUBSIDIARIES | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| As of June 30, 2017 and December 31, 2016 | ||||||||
| (Unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2017 | 2016 | |||||||
| ASSETS | ||||||||
| Cash and Cash Equivalents | $ | 8,327,695 | $ | 17,180,594 | ||||
| Investments Available for Sale | 34,914,331 | 40,759,703 | ||||||
| Accounts Receivable, net of a reserve of $7,000 in 2017 and $5,000 in 2016 | 4,880,969 | 6,393,228 | ||||||
| Inventory | 13,774,065 | 12,141,072 | ||||||
| Other Current Assets | 1,907,270 | 2,034,598 | ||||||
| Total Current Assets | 63,804,330 | 78,509,195 | ||||||
| Property and Equipment, net | 1,529,639 | 1,391,575 | ||||||
| Inventory, Non-Current | 2,725,958 | 1,826,554 | ||||||
| Intangible Assets | 4,205 | 4,382 | ||||||
| Goodwill | 920,745 | 920,745 | ||||||
| Other Non-current Assets | 490,738 | 501,187 | ||||||
| Total Assets | $ | 69,475,615 | $ | 83,153,638 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Accounts Payable | $ | 3,869,646 | $ | 5,858,234 | ||||
| Accrued Liabilities | 3,585,198 | 4,210,151 | ||||||
| Customer Deposits | 212,320 | 77,217 | ||||||
| Total Current Liabilities | 7,667,164 | 10,145,602 | ||||||
| Deferred License Revenue | 17,962,468 | 20,051,737 | ||||||
| Shareholders’ Equity: | ||||||||
| Common Shares, no par value, 51,740,040 and 51,527,711 shares issued and outstanding | 270,302,780 | 268,199,939 | ||||||
| Accumulated Deficit | (226,166,099 | ) | (214,341,092 | ) | ||||
| Accumulated Other Comprehensive Income | (290,698 | ) | (902,548 | ) | ||||
| Total Shareholders’ Equity | 43,845,983 | 52,956,299 | ||||||
| Total Liabilities And Shareholders’ Equity | $ | 69,475,615 | $ | 83,153,638 | ||||
| ROCKWELL MEDICAL, INC. AND SUBSIDIARIES | ||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| For the six months ended June 30, 2017 and June 30, 2016 | ||||||||
| (Unaudited) | ||||||||
| 2017 | 2016 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net (Loss) | $ | (11,825,007 | ) | $ | (10,185,356 | ) | ||
| Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities: | ||||||||
| Depreciation and Amortization | 259,084 | 395,990 | ||||||
| Share Based Compensation—Non-employee | 88,487 | — | ||||||
| Share Based Compensation—Employees | 4,301,585 | 5,222,723 | ||||||
| Loss on Disposal of Assets | 3,634 | 258 | ||||||
| Loss (gain) on Sale of Investments Available for Sale | 368,519 | (3,302 | ) | |||||
| Changes in Assets and Liabilities: | ||||||||
| Decrease (Increase) in Accounts Receivable | 343,993 | (2,543,404 | ) | |||||
| (Increase) in Inventory | (2,532,397 | ) | (3,137,896 | ) | ||||
| Decrease (Increase) in Other Assets | 349,378 | (54,132 | ) | |||||
| Increase (Decrease) in Accounts Payable | (1,988,717 | ) | 980,981 | |||||
| Increase (Decrease) in Other Liabilities | (489,857 | ) | 106,441 | |||||
| (Decrease) in Deferred License Revenue | (996,240 | ) | (963,372 | ) | ||||
| Increase (Decrease) in Deferred Drug License Revenue | (136,362 | ) | 3,886,365 | |||||
| Changes in Assets and Liabilities | (5,450,202 | ) | (1,725,017 | ) | ||||
| Cash (Used In) Operating Activities | (12,253,900 | ) | (6,294,704 | ) | ||||
| Cash Flows From Investing Activities: | ||||||||
| Purchase of Investments Available for Sale | (27,262,362 | ) | (9,259,648 | ) | ||||
| Sale of Investments Available for Sale | 33,351,339 | 8,328,987 | ||||||
| Purchase of Equipment | (401,055 | ) | (229,287 | ) | ||||
| Proceeds on Sale of Assets | 450 | 1,000 | ||||||
| Cash Provided by (Used In) Investing Activities | 5,688,372 | (1,158,948 | ) | |||||
| Cash Flows From Financing Activities: | ||||||||
| Proceeds from Issuance of Common Shares | — | 77,250 | ||||||
| Restricted Stock Retained in Satisfaction of Tax Liabilities | (2,287,231 | ) | — | |||||
| Cash Provided By (Used In) Financing Activities | (2,287,231 | ) | 77,250 | |||||
| Effects of exchange rate changes | (140 | ) | — | |||||
| (Decrease) Increase In Cash | (8,852,899 | ) | (7,376,402 | ) | ||||
| Cash At Beginning Of Period | 17,180,594 | 31,198,182 | ||||||
| Cash At End Of Period | $ | 8,327,695 | $ | 23,821,780 | ||||